Radius Health Stock

Radius Health ROE

Delisted·Jul 10, 2025

The Return on Equity (ROE) of Radius Health (RDUS) as of Aug 12, 2026 is -42.75 %. In the previous year, Return on Equity (ROE) was -2.84 % — a change of 1,405.53% (lower).

ROE

-42.75 %

YoY

1,405.53%

Last updated:

In 2026, Radius Health's return on equity (ROE) was -42.75 %, a 1,405.53% increase from the -2.84 % ROE in the previous year.

Access this data via the Eulerpool API
Get Free API Key

Radius Health Stock analysis

What does Radius Health do? Radius Health Inc. is an American pharmaceutical company specializing in the research, development, and marketing of products in the areas of osteoporosis, cancer therapy, and endocrinology. The company was founded in 2003 and is headquartered in Waltham, Massachusetts. The history of Radius Health Inc. began with the discovery of a new compound called Abaloparatide, which was intended for use in the treatment of osteoporosis. The company initiated a Phase III clinical trial to evaluate the efficacy and tolerability of the medication. In 2016, Abaloparatide was approved by the U.S. Food and Drug Administration (FDA) for the treatment of postmenopausal osteoporosis. Since then, Radius Health Inc. has evolved into a leading company specializing in improving women's health. The company has expanded its activities to include oncology and endocrinology and relies on innovative technologies and research to provide better treatment options and medications for patients. The business model of Radius Health Inc. is based on the development and marketing of cost-effective and effective products for the treatment of diseases. The company conducts extensive clinical research and strives to develop new drugs and therapies to improve the lives of women. Radius Health Inc. employs an open and agile corporate culture that promotes innovation and prioritizes the needs of patients. The products offered by Radius Health Inc. include a wide range of medications used in the treatment of osteoporosis, breast cancer, and other diseases. Abaloparatide, the company's flagship product, is a recombinant peptide agonist that stimulates bone formation and reduces the risk of fractures in postmenopausal women. Other products include Elacestrant, an investigative drug for the treatment of breast cancer, and RAD1901, a selective estrogen receptor modulator used in the treatment of hormone-dependent cancers. The company is also active in the field of digital health. Radius Health Inc. has developed an augmented reality app that assists doctors and patients in visualizing bone fractures and other conditions. The app is currently being tested in clinical trials and is expected to be widely used in the future. Overall, Radius Health Inc. is known for its innovative research activities and efforts to improve women's health. The company has an experienced and dedicated team of researchers, scientists, and executives working together to create better treatment options for patients. With a strong pipeline of products and a vision for the future of healthcare, Radius Health Inc. is on track to become a leading provider of medical products and services. Radius Health is one of the most popular companies on Eulerpool.

ROE Details

Decoding Radius Health's Return on Equity (ROE)

Radius Health's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Radius Health's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Radius Health's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Radius Health’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Radius Health stock

Return on Equity (ROE) of Radius Health is -42.75 % in 2026.

Return on Equity (ROE) of Radius Health changed from -2.84 % to -42.75 %, representing a 1,405.53% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Radius Health since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Radius Health with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API
Get Free API Key

Profitability — Radius Health

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Radius Health